$1495 | Single User
$2295 | Multi User
$4495 | Site License
$7495 | Global License

Global Chronic Kidney Disease Partnering 2010 to 2016

Published by Current Partnering: 01 Nov 2016 | 20362 | In Stock

Introduction

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.

• Trends in partnering deals

• Top deals by value

• Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies.


The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.


This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of partnering trends.


Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.


Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.


Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.


Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Table of Contents
for Global Chronic Kidney Disease Partnering 2010 to 2016

  • Executive Summary

    Chapter 1 - Therapypartnering trends in numbers

    Partnering in numbers – by year

    Partnering in numbers – most active

    Partnering in numbers – by industry sector

    Partnering in numbers – by deal type

    Partnering in numbers – by technology type

    Partnering in numbers – by stage of development

    Chapter 2 - Most active dealmakers

    Chapter 3 - Partnering deals directory

    Partnering deals directory – by company A-Z

    Partnering deals directory – by deal value

    Partnering deals directory – by industry sector

    Partnering deals directory – by deal type

    Partnering deals directory – by stage of development

    Partnering deals directory – by technology area

    Chapter 4 - Partnering deals with a contract document

    Chapter 5 - M&A in numbers

    M&A in numbers – by year

    Chapter 6 - M&A deals directory

    M&A deals directory – by company A-Z

    M&A deals directory – by deal value

    Chapter 7 - Financing in numbers

    Financing in numbers – by year

    Financing in numbers – by financing type

    Chapter 8 - Financing deals directory

    Financing deals directory – by company A-Z

    Financing deals directory – by deal value

    Financing deals directory – by financing type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent titles from CurrentPartnering

    TABLE OF FIGURES

    Figure 1: Partnering frequency by year

    Figure 2: Partnering most active

    Figure 3: Partnering by industry sector

    Figure 4: Partnering by deal type

    Figure 5: Partnering by technology area

    Figure 6: Partnering by stage of development

    Figure 7: M&A frequency by year

    Figure 8: Financing frequency by year

    Figure 9: Financing by type

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

20362 | CP2208chr

Number of Pages

150

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
The Outlook for Wearable Health Tech in Managing Chronic Disease
IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
01 May 2016 by FirstWord Pharma USD $695 More Info
Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
20 Apr 2015 by FirstWord Pharma USD $7,900 More Info
Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
27 May 2014 by FirstWord Pharma USD $7,900 More Info
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
20 Jan 2014 by FirstWord Pharma USD $7,495 More Info
Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
01 Jun 2013 by FirstWord Pharma USD $695 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Chronic Kidney Disease Partnering 2010 to 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data